5.64
-0.09 (-1.57%)
| Penutupan Terdahulu | 5.73 |
| Buka | 5.75 |
| Jumlah Dagangan | 7,724,717 |
| Purata Dagangan (3B) | 4,671,779 |
| Modal Pasaran | 1,736,730,880 |
| Harga / Pendapatan (P/E Ke hadapan) | 49.02 |
| Harga / Jualan (P/S) | 3.47 |
| Harga / Buku (P/B) | 9.82 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
| Margin Keuntungan | -5.41% |
| Margin Operasi (TTM) | -6.35% |
| EPS Cair (TTM) | -0.090 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 13.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 229.11% |
| Nisbah Semasa (MRQ) | 3.34 |
| Aliran Tunai Operasi (OCF TTM) | 3.56 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 29.27 M |
| Pulangan Atas Aset (ROA TTM) | 3.95% |
| Pulangan Atas Ekuiti (ROE TTM) | -18.12% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Amicus Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 1.38 |
|
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.75% |
| % Dimiliki oleh Institusi | 102.83% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 22.00 (UBS, 290.07%) | Beli |
| Median | 15.50 (174.82%) | |
| Rendah | 9.00 (Goldman Sachs, 59.57%) | Pegang |
| Purata | 15.50 (174.82%) | |
| Jumlah | 1 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 6.67 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Goldman Sachs | 02 May 2025 | 9.00 (59.57%) | Pegang | 6.67 |
| UBS | 02 May 2025 | 22.00 (290.07%) | Beli | 6.67 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 25 Jun 2025 | Pengumuman | Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan |
| 03 Jun 2025 | Pengumuman | New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve |
| 30 May 2025 | Pengumuman | Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 |
| 07 May 2025 | Pengumuman | Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference |
| 01 May 2025 | Pengumuman | Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates |
| 30 Apr 2025 | Pengumuman | Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States |
| 21 Apr 2025 | Pengumuman | Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |